✦ LIBER ✦

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

✍ Scribed by Michael G Kaplitt; Andrew Feigin; Chengke Tang; Helen L Fitzsimons; Paul Mattis; Patricia A Lawlor; Ross J Bland; Deborah Young; Kristin Strybing; David Eidelberg; Matthew J During

Book ID: 117301366
Publisher: The Lancet
Year: 2007
Tongue: English
Weight: 247 KB
Volume: 369
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(07)60982-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and tolerability of intraputamina

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

✍ William J Marks Jr; Jill L Ostrem; Leonard Verhagen; Philip A Starr; Paul S Lars 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 169 KB

Long-term safety and tolerability of Pro

Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial

✍ Palfi, Stéphane; Gurruchaga, Jean Marc; Ralph, G Scott; Lepetit, Helene; Lavisse 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 657 KB

Phase I/II Trial of Adeno-Associated Vir

Phase I/II Trial of Adeno-Associated Virus–Mediated Alpha-Glucosidase Gene Therapy to the Diaphragm for Chronic Respiratory Failure in Pompe Disease: Initial Safety and Ventilatory Outcomes

✍ Smith, Barbara K.; Collins, Shelley W.; Conlon, Thomas J.; Mah, Cathryn S.; Laws 📂 Article 📅 2013 🏛 Mary Ann Liebert 🌐 English ⚖ 530 KB